Clinical use of H7N9 vaccines could be years away  

數(shù)個(gè)H7N9疫苗已申報(bào) 臨床試驗(yàn)仍需時(shí)間

針對(duì)H7N9禽流感病毒疫苗的研發(fā)，數(shù)家公司及機(jī)構(gòu)已有不少突破性進(jìn)展。業(yè)內(nèi)人士表示，一個(gè)新疫苗，從臨床前研究到臨床試驗(yàn)再到獲批上市，還須經(jīng)過很多謹(jǐn)慎的研究、審核環(huán)節(jié)和足夠的時(shí)間(一般為2年至3年)。[查看全文]

(ECNS) -- Several vaccines for H7N9 bird flu are waiting for approval in clinical trials, but it will take years before the vaccines can be used on humans, the Beijing News reported on Sunday.

The Shanghai Public Health Clinical Center (SPHCC) announced that its genetically-engineered vaccine for H7N9 avian influenza passed preliminary testing on laboratory mice last week.

The newspaper said it is not the country's first, as at least two biomedicine companies have applied for H7N9 vaccines to undergo clinical trials, but none of them have received approval from the China Food and Drug Administration.

Experts say that clinical tests are still at an early stage for vaccines, and that it usually takes two or three years before they can be used on humans.

China Business News cited Xu Jianqing, an official at the SPHCC, as saying that clinical trials include three phases covering at least six years. Risk is also involved during the process, he added.

A vaccine producer said genetically-engineered vaccines need more time to come onto the market, as producers must launch new production lines and apply for new GMP (Good Manufacturing Practices) certificates.

China reported more human cases of H7N9 on Saturday after researchers in Shanghai announced preliminary success in developing a vaccine, according to Xinhua.